Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cross-reactivity

Cross-reactivity

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Vaccinations

Vaccinations

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Persistence of memory: lifespan dynamics of the human antiviral antibody reactome.

Nature communications·2026

Same author

Comorbidities and lifestyle changes as predictors of the multiple sclerosis prodrome: A prospective cohort study.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026

Same author

The association between COVID-19 vaccines and bullous pemphigoid risk: A UK population-based study.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026

Same author

Healthy Dietary Patterns and Risk of Parkinson's Disease.

Movement disorders : official journal of the Movement Disorder Society·2026

Same author

Shotgun Metagenomic Profiling of the Gut Virome in Prodromal and Confirmed Parkinson's Disease.

Annals of neurology·2026

Same author

Pre-Diagnostic Plasma Carotenoids, Tocopherols and Retinol Levels, and Risk of Amyotrophic Lateral Sclerosis.

Annals of neurology·2026

Search research articles

Related Experiment Video

Updated: Sep 5, 2025

Separation of Immune Cell Subpopulations in Peripheral Blood Samples from Children with Infectious Mononucleosis

Separation of Immune Cell Subpopulations in Peripheral Blood Samples from Children with Infectious Mononucleosis

Published on: September 7, 2022

The Potential for EBV Vaccines to Prevent Multiple Sclerosis.

Peter A Maple^1,2, Alberto Ascherio^3,4, Jeffrey I Cohen⁵

¹Division of Clinical Neuroscience, Section of Clinical Neurology, University of Nottingham, Nottingham, United Kingdom.

Frontiers in Neurology

|July 11, 2022

Summary

This summary is machine-generated.

Epstein-Barr virus (EBV) infection is linked to multiple sclerosis (MS). While a gp350 vaccine shows promise for preventing infectious mononucleosis (IM), its effect on MS requires further investigation through national registry studies.

Keywords:

Epstein-Barr virus (EBV)epidemiological evidence multiple sclerosis prophylactic vaccination vaccine evaluation

More Related Videos

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Related Experiment Videos

Last Updated: Sep 5, 2025

Separation of Immune Cell Subpopulations in Peripheral Blood Samples from Children with Infectious Mononucleosis

Separation of Immune Cell Subpopulations in Peripheral Blood Samples from Children with Infectious Mononucleosis

Published on: September 7, 2022

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Area of Science:

Virology
Immunology
Neurology

Background:

Epstein-Barr virus (EBV), a human herpesvirus, infects most adults, often asymptomatically.
EBV infection is associated with infectious mononucleosis (IM), lymphoproliferative disorders, and certain malignancies.
Emerging evidence suggests a causal link between EBV infection and the development of multiple sclerosis (MS).

Purpose of the Study:

To explore the potential of vaccination as an intervention against EBV-associated diseases.
To evaluate the efficacy of a prophylactic EBV vaccine, specifically targeting the gp350 glycoprotein.
To address the challenges in assessing vaccine impact on MS due to its delayed onset after EBV infection.

Main Methods:

Review of existing evidence linking EBV to MS.
Analysis of data from a Phase 2 clinical trial of a gp350-based EBV vaccine.
Discussion of the necessity for national registry studies to monitor MS incidence in vaccinated vs. unvaccinated populations.

Main Results:

The gp350 vaccine demonstrated a 78% reduction in infectious mononucleosis (IM) rates in a Phase 2 study.
The vaccine did not prevent EBV infection itself.
The average age of MS onset is approximately 30, posing challenges for vaccine efficacy assessment.

Conclusions:

Vaccination against EBV, particularly to prevent IM in adolescents and young adults, is a viable public health strategy.
Long-term national registry studies are crucial to determine if EBV vaccination can reduce the incidence of multiple sclerosis.
Assessing the long-term impact of EBV vaccination on MS requires careful monitoring due to the disease's delayed manifestation.